Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

367
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medication for subcutaneous administration: Microbiological and physicochemical stability of drug formulations prepared in advance and stored in syringes.

Palliative care and social practice·2026
Same author

FEASIBILITY AND INTERIM SAFETY AND EFFICACY ANALYSIS OF A FAST AUTOMATED PRODUCTION OF PROPHYLACTIC CMV-SPECIFIC CTLs AFTER ALLOGENEIC HSCT.

Transplantation and cellular therapy·2026
Same author

Cord blood-derived mesenchymal stromal cells in children with steroid-dependent nephrotic syndrome: a prospective phase II study.

Clinical kidney journal·2026
Same author

The functional relevance of human leukocyte antigens in the development of cord blood derived advanced cellular therapies: A new direction of public cord blood banks.

Human immunology·2026
Same author

Use of mesenchymal stromal cells derived from the Wharton's jelly of human umbilical cord for treating patients with steroid-resistant graft versus host disease: predicting clinical response by a validated immunopotency assay.

Scientific reports·2026
Same author

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.

Cytotherapy·2026

Related Experiment Video

Updated: Jul 31, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.9K

Multi-component cord blood banking: a proof-of-concept international exercise.

Dinara Samarkanova1,2, Margarita Codinach1,2, Tiziana Montemurro3

  • 1Banc de Sang i Teixits, Barcelona, Spain.

Blood Transfusion = Trasfusione Del Sangue
|May 5, 2023
PubMed
Summary

This study developed a standardized protocol for processing cord blood (CB) components, yielding platelet concentrate, plasma, and red blood cells. The MultiCord12 protocol demonstrated high compliance, offering a viable method for utilizing otherwise discarded CB units.

More Related Videos

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

10.0K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.2K

Related Experiment Videos

Last Updated: Jul 31, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.9K
Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

10.0K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.2K

Area of Science:

  • Regenerative Medicine
  • Biotechnology
  • Hematology

Background:

  • Public cord blood banks discard over 80% of units unsuitable for transplantation due to low stem cell counts.
  • Existing experimental uses of cord blood platelets, plasma, and red blood cells lack standardized preparation protocols.
  • This highlights a significant unmet need for efficient utilization of cord blood resources.

Purpose of the Study:

  • To develop and validate a standardized protocol for the routine production of cord blood platelet concentrate (CB-PC), platelet-poor plasma (CB-PPP), and leukoreduced red blood cells (CB-LR-RBC).
  • To assess the feasibility of using locally available equipment and commercial devices across multiple international cord blood banks.
  • To establish acceptance criteria for these processed cord blood components.

Main Methods:

  • A network of 12 public cord blood banks implemented the MultiCord12 protocol using double centrifugation and filtration.
  • Specific acceptance criteria were defined for CB-PC (volume, platelet count), CB-PPP (platelet count), and CB-LR-RBC (volume, hematocrit, residual leukocytes, hemolysis).
  • Cord blood red blood cells were processed with SAGM, leukoreduced, stored, and tested for hemolysis and potassium release over 15 days.

Main Results:

  • Eight banks completed validation, achieving high compliance rates: 99% for CB-PC minimum volume, 86.1% for CB-PC platelet count, and 90% for CB-PPP platelet count.
  • CB-LR-RBC showed 85.7% compliance for minimum volume, 98.9% for residual leukocytes, and 90% for hematocrit.
  • Hemolysis compliance decreased from 89.0% to 63.2% over 15 days, with potassium release increasing significantly.

Conclusions:

  • The MultiCord12 protocol provides a valuable framework for the preliminary standardization of cord blood-derived platelet concentrate, plasma, and red blood cells.
  • The protocol demonstrates potential for routine production and utilization of these components from otherwise discarded cord blood units.
  • Further optimization may be needed to address long-term storage stability, particularly regarding hemolysis and potassium levels in red blood cells.